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Abstract 
 
Background data: Narrow band UVB is an effective and safe option for the 
treatment of vitiligo. However, a complete and long-lasting repigmention of vitiligo 
patches is difficult to achieve. Combined treatments with novel sources of 
phototherapy and topical agents represent possible new strategies.  
Objective: The purpose of this study was to compare the efficacy of combined 
tacrolimus and 308-nm excimer light (MEL) vs 308-nm MEL monotherapy in 
treating vitiligo in a controlled study.  
Methods: Fifty-three patients affected by vitiligo were enrolled in this open 
prospective study. Patients were divided into three groups: Group I included 20 
patients treated with MEL 308nm twice weekly and oral vitamin E; Group II 
included 20 patients treated with MEL 308nm twice weekly combined with 0.1% 
tacrolimus once a day and oral vitamin E; and Group III included 13 patients 
treated only with oral vitamin E. Efficacy was assessed at the end of 12 weeks 
based on the percentage of repigmentation.  
Results: Fifty-two patients completed 12 weeks of treatment. Group I (MEL + 
vitamin E) showed a moderate repigmentation in 35% of patients, good 
repigmentation in 30%, excellent repigmentation in 25%, and poor 
repigmentation in 10%; Group II (MEL + tacrolimus 0.1% + vitamin E) presented 
moderate repigmentation in 25% of patients, good repigmentation in 40%, 
excellent repigmentation in 30%, and poor repigmentation in 5%; Group III 
(vitamin E) showed moderate repigmentation in 16% and 84% did not show signs 
of repigmentation.  
Conclusions: Our results demonstrate that the combination treatment of 0.1% 
tacrolimus ointment plus 308-nm MEL and 308-nm MEL monotherapy are 
effective, safe, and well tolerated for the treatment of vitiligo compared to 
treatment with vitamin E. Furthermore, this study suggests that an association 
with topical immunomodulators could enhance the clinical response in vitiligo, 
especially in more resistant anatomical sites 
 
 
 
Introduction 
 
Vitiligo is an acquired idiopathic hypomelanosis, characterized by the 
appearance of depigmented areas, affecting ~1–2% of the world population.1,2 
There are no apparent differences in rates of occurrence according to race 
and sex.2 The pathogenesis is still unclear, but immunemediated mechanisms 
are considered the most probable causes leading to loss of functional 
melanocytes in the epidermis and in the follicles.3 Clinically, it is characterized by 
amelanotic areas that vary in size during the course of the disease, and are often 
symmetrically distributed, involving periorificial and frictional areas. 
Many therapeutic options have been suggested for the treatment of vitiligo, 
including nonsurgical and surgical modalities, most of them directed toward 
increasing melanocyte melanin production, and fewer addressing the 
immunologic nature of the disease.4 
Surgical modalities, such as autologous transplantation (split-thickness epidermal 
grafting, epidermal blister grafting, and grafting of cultured of melanocytes) are 
invasive and not well accepted by most of the patients. Nonsurgical modalities, 
considered the first line therapy, include topical, intra-lesional, and systemic 
corticosteroids, topical and oral psoralen plus ultraviolet A (PUVA), topical khellin 
3–5%, broad band and narrow band (NB-UVB 311nm UVB phototherapy), and, 
more recently, topical immunomodulators (i.e., tacrolimus, pimecrolimus).4–8 
A validated and novel therapeutic option is represented by monochromatic 
excimer light (MEL) Micro, which is a 308-nm XeCl device capable of emitting a 
power density of 50 mW/cm2 on a maximum irradiated area of 30 cm2 (from 
0.8 cm2 to 30 cm2).8 
A novel localized treatment of vitiligo is represented by the application of topical 
immunomodulators (TIMs). Tacrolimus modulates the immune system by 
inhibiting T-cell activation via downregulation of the transcription genes encoding 
pro-inflammatory cytokines (IL-2, IL-3, IL-4, IL-5, interferon-γ, tumor necrosis 
factor-α, granulocytemacrophage colony stimulating factor).9–11 Some authors 
have highlighted the possible synergistic activity of topical tacrolimus plus UVB 
phototherapy, with either NB-UVB or excimer radiation through the activation of 
pathways influencing the process of melanocyte mitogenesis, melanocyte 
migration, and melanogenesis.12–14 
The aim of this prospective, controlled, randomized, pilot study was to evaluate 
the efficacy and safety of the association of 0.1% tacrolimus ointment plus the 
308-nm excimer light compared with 308-nm excimer light monotherapy in 
the treatment of vitiligo. 
 
Patients and methods 
 
The study was approved by the ‘‘Policlinico Tor Vergata’’ ethical committee. All 
patients enrolled in the study provided written informed consent. 
Fifty-three patients (27 male and 26 female), aged between 13 and 56 years 
(mean age 28 years), affected by localized and generalized vitiligo (acrofacial 
and segmental type) were enrolled in this open pilot prospective study. Those 
with vitiliginous patches ≥ 2 cm2 who had been stable over the last 6 months 
were randomly selected for treatment, and one to three symmetrical patches 
were irradiated. 
MEL Micro (MEL, Excilite® μ DEKA Medical Lasers, Florence, Italy) is a 308-nm 
XeCl device capable of emitting a power density of 50 mW/cm2 on a variable 
area from 0.8 cm2  to 30 cm2, in order to concentrate treatment only on affected 
skin. 
Patients were randomly divided into three groups: 1) Group I (MEL + vitamin E) 
included 20 patients treated with MEL Micro 308 twice a week and oral vitamin E 
400 IU twice a day; 2) Group II (MEL + 0.1% tacrolimus + vitamin E) included 20 
patients treated with MEL Micro 308 twice a week, 0.1% tacrolimus ointment 
once a day, and oral vitamin E 400 UI twice a day; and 3) Group III (Vitamin E – 
control group) included 13 patients treated with oral vitamin E 400 UI twice a day. 
Exclusion criteria included: topical or systemic treatments and phototherapy 
during the previous 3 months, photosensitivity, photomediated disorders, 
radiotherapy, systemic immunosuppressive treatments, immunosuppressive 
diseases, history of skin cancer, pregnant and breast-feeding women, and age 
<10 years. 
Group I and II patients were phototested with MEL on normally pigmented and 
unexposed skin. The minimal erythemal dose (MED) was determined at 
increasing light dosages following the initial dose of MEL, which was calculated 
according to patient’s skin type (Table 1). 
An initial dose of 75% of the MED reported for MEL was applied and increased at 
subsequent treatments by 0.25 J/cm2–0.75 J/cm2 of the dose used in the 
previous session, according to the erythematous response. The peripheral area 
of each single patch was protected from irradiation with a topical sunscreen 
applied 1 h prior to treatment. During therapy, when marked erythema occurred, 
the next dose was reduced by 25% of the previous dose. 
Tacrolimus 0.1% ointment (Protopic®, Astellas) was topically administered once 
daily on single patches of patients included in Group II. Patients continued 
application of tacrolimus 0.1% regardless of phototherapeutic erythematous 
reaction. Minimizing or avoiding natural or artificial sunlight exposure during 
tacrolimus ointment treatment was recommended. 
Two oral daily vitamin E capsules (Sursum® 400 UI, Abiogen) were prescribed to 
all patients for the whole period of the study, according to the role of oxidative 
stress in several cutaneous diseases including vitiligo.15 
During the pre-treatment visit and after 12 weeks of therapy, patients were 
assessed by physical examination, photographic documentation, and monitoring 
of adverse events. 
Assessment of treatment efficacy performed by two independent physicians was 
based on the percentage of repigmentation in the treated area. Repigmentation 
was assessed in four categories: ‘‘no changes–poor repigmentation’’ ( = 25%), 
‘‘moderate repigmentation’’ (25–50%), ‘‘good repigmentation’’(51–75%), and 
‘‘excellent repigmentation’’ (76–100%), as reported by various authors.8,16 
Safety assessments, including adverse events and vital signs, were assessed 
throughout the study and spanned a period through 120 days after the last 
treatment. 
 
Statistical analysis 
 
The significance of difference between percentages in groups was evaluated with 
the χ² test. A p value of < 0.05 was considered to indicate statistical significance. 
Statistical analyses were performed using SPSS for Windows (version 15.0). 
 
 
TABLE 1. MED (MINIMAL ERYTHEMATOUS DOSE) 
AT 308 NM, ACCORDING TO PHOTOTYPE 
 
Phototype MED 
I 4 sec 200m J/cm2 
II 5 sec 250m J/ cm2 
III 4 sec 300-350m J/cm2 
IV 7-8 sec 350-400m J/cm2 
 
 
Results 
 
All patients treated with excimer light monotherapy or in combination with 
tacrolimus 0.1% completed the 12 weeks of treatment whereas in the control 
group, one patient discontinued the study after 3 weeks. Clinical features of 
treated patients are reported in Table 2.  
Patients had a Fitzpatrick skin phototype ranging from II to IV. Considering each 
study group, the results were as follows: 1) Group I (MEL + vitamin E) showed 
moderate repigmentation in 7/20 (35%) patients, good repigmentation in 6/20 
(30%) patients, excellent repigmentation in 5/20 (25%) patients, and poor 
repigmentation in 2/20 (10%) patients; 2) Group II (MEL + tacrolimus 0.1% + 
vitamin E) presented moderate repigmentation in 5/20 (25%) patients, good 
repigmentation in 8/20 (40%) patients, excellent repigmentation (Fig. 1) in 6/20 
(30%) patients, and poor repigmentation in 1/20 (5%) patients; 3) Group III 
(vitamin E) showed a moderate repigmentation in 2/13 (16%) patients, 10/13 
(76%) patients did not show signs of repigmentation and 1 patient 1/13 (8%) 
discontinued the treatment because of lack of efficacy. 
Percentage of repigmentation was significant higher in Groups I and II than in 
Group III (p < 0.001). Clinical response between Group I and Group II did not 
show statistical significance (p = 0.36) (Fig. 2). 
The mean total dose at the end of treatment was 19.3 J/cm2 and 21.7 J/cm2 in 
Groups I and II, respectively. 
No side effects, such as burning and blistering, were observed in any of the 
patients treated, although mild side effects were observed such as symptomatic 
erythema, burning/pain, stinging, and peri-lesional hyperpigmentation in 30% of 
patients and 25% of patients in Groups I and II, respectively. 
Treatments were well tolerated, and at the 120-day followup visit adverse events 
related to therapies were not reported. 
 
TABLE 2. PATIENT DEMOGRAPHICS AND DISEASE CHARACTERISTICS AT BASELINE. 
STUDY GROUPS WERE BALANCED FOR NUMBER, DEMOGRAPHIC, AND DISEASE 
FEATURES 
 
 Group I Group II Group III 
Mean age ± SD 31.95 ± 14.07 26.4 ± 11.5 29 ± 12.35 
Male/female 11/9 10/10 7/6 
Race Caucasian Caucasian Caucasian 
Fitzpatrick skin type (I-V) II 5 patients 
III 13 patients 
IV 2 patients 
II 8 patients 
III 9 patients 
IV 3 patients 
II 5 patients 
III 5 patients 
IV 3 patients 
Mean duration of disease 
(months) 
30 26 20 
Mean number of sessions 23 23 - 
Mean total dose (range for 
session) (J/cm2) 
19.3 (0.25-1.65) 21.7 (0.30-1.75) - 
Number of sessions to 
onset of repigmentation 
11 9 - 
Type of vitiligo (number of 
patients) 
Segmental (2) 
Generalized (18) 
Segmental (2) 
Generalized (18) 
Segmental (1) 
Generalized (12) 
 
   
FIG.1. Facial vitiligo before treatment with MEL + 0.1% tacrolimus + vitaminE (a); 
repigmentation after 4 weeks (b), 8 weeks (c), and 12 weeks (d). 
 
 
 
 
Discussion 
 
Our results demonstrate that the combined treatment of 308-nm excimer light 
and 0.1%  acrolimus ointment (MEL + tacrolimus 0.1% + vitamin E) proved more 
effective than either MEL + vitamin E or vitamin E alone. It is noteworthy that 
good–excellent repigmentation was observed in 70% of patients treated with the 
combination of tacrolimus and MEL and in 55% of the MEL monotherapy group. 
Among therapeutic options suggested for the treatment of vitiligo, phototherapy is 
considered safe and effective. 4 Furthermore, both excimer lasers and light 
sources showed a more rapid onset of repigmentation, less frequent applications, 
and possibility of a selective irradiation of vitiligo patches without a perilesional 
skin involvement.16,17 
However, our clinical experience in the treatment of vitiligo suggests that no 
treatment provides satisfactory results in all patients. For this reason, we believe 
that combined therapies could be a novel option in the treatment of vitiligo, as the 
synergistic action of different treatment could induce better results, minimizing 
adverse events. 
We have previously showed, in an open pilot study, that the efficacy of excimer 
light can be enhanced by combination with the photosensitizer khellin. We found 
that this combination improved the percentage of repigmentation and rate of 
clinical response in resistant anatomical sites.18 
Similarly, we hypothesize that in a cutaneous immunomediated disorder such as 
vitiligo, the use of TIMs could enhance the effect of phototherapy, inducing faster 
repigmentation with long-term results. Evidence of this possible mechanism of 
action comes from the study of Castanedo-Cazares et al.,13 showing that after 6 
months of traditional NB UVB phototherapy, an additional 3 months’ application 
of tacrolimus 0.1% induced a further 25% improvement in repigmentation. 
The association of phototherapies with TIMs in the treatment of vitiligo has been 
reported by other authors.14,19,20 Passeron et al.19 reported, in a controlled study 
performed in 14 patients, that the combination treatment of 0.1% tacrolimus 
ointment plus 308-nm excimer laser was more effective than 308-nm excimer 
laser as a monotherapy and controls, for achieving a repigmentation rate of at 
least 75%. 
In another pilot study,12 it was reported that of the 24 vitiliginous patches treated 
with excimer laser 308 nm, in combination with tacrolimus 0.1% ointment, 50% 
achieved a successful response (75% repigmentation) at a significantly faster 
rate than that of other vitiliginous patches treated with excimer laser and placebo, 
which achieved only 20% success. 
Similar to the aforementioned studies, we reported a good–excellent 
repigmentation in 70% of patients treated with the combination of MEL and 
tacrolimus, whereas in the MEL monotherapy treated group, we observed a 
good–excellent repigmentation only in 55% of patients. Moreover, we found that 
the onset of repigmentation occurred after a mean of 11 and 9 sessions, 
respectively, in Groups I and II. This was in accordance with the mean total dose: 
the mean cumulative dose of MEL was higher in Group II than in Group I, 
suggesting that tacrolimus increased the tolerability to phototherapy through an 
immunomodulator mechanism. As a consequence, the higher percentage of 
clinical response observed in Group II compared to Group I could be caused by 
both the higher cumulative dose and the immunodulatory effect of tacrolimus. 
The rapid efficacy and the total number of applications confirmed previous 
observations reported by Passeron et al.19  In contrast to the latter, we reported 
the efficacy and the rapid mechanism of action of the combined therapy in a 
larger group of patients. Furthermore, the safety was assessed through a long-
term follow-up of 120 days. 
The association of excimer light phototherapy and tacrolimus ointment offered 
encouraging results in terms of patient compliance with the given therapeutic 
protocol, as it was well tolerated, not time consuming, and easy to administer. 
Furthermore, even if it was not reported in this study, patients noted a significant 
improvement of their quality of life, less embarrassment during relationships, 
improvement of their body image, and a more optimistic attitude towards life and 
their disease when treatment was effective (data not shown). These findings 
were not reported in patients affected with localized vitiligo, who showed a 
poor response to medical treatment in all groups. 
The use of a TIM in association with phototherapy gives rise to concerns about 
the possible increased risk of skin carcinogenesis.20 On the other hand, results of 
a recent study suggest that topical calcineurin inhibitors do not affect the 
clearance of DNA photoproducts preventing DNA photodamage, because of a 
filter effect of both vehicle and active components.21 Moreover, as previously 
discussed, the use of tacrolimus may be useful to prevent UVB-induced 
erythema by inhibiting early-phase events of the inflammatory process.12–14 
Finally, addition of tacrolimus to excimer phototherapy could be another option 
for vitiligo patients, considering the lower cancerogenesis profile compared with 
systemic administration, and the quicker repigmentation effect. 
In conclusion, our results confirm the efficacy of excimer light therapy in vitiligo 
as reported by other authors,8,17 and suggest that an association with TIMs such 
as tacrolimus, which address the immunologic nature of the disease, could 
enhance the clinical response, especially in more resistant anatomical sites, 
without an increase in side effects. 
Therefore, combination of UV light and TIMs may represent an advance in the 
treatment of the disease. 
 
Conclusions 
 
Our results confirm the efficacy of excimer light therapy in vitiligo, suggesting that 
an association with TIMs may represent an advance in the treatment of the 
disease. Furthermore, this study suggests that an association with TIMs could 
enhance the clinical response in vitiligo, especially in more resistant anatomical 
sites, without an increase in side effects. Indeed, this combination could enhance 
the clinical response interfering with immunological pathways involved in the 
pathogenesis of the disease. However, further studies are mandatory in order to 
identify therapeutic protocols and a long-term safety profile according to 
phototype and vitiligo phenotype. 
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FIG. 2. The chart shows the percentage of patients achieving an excellent, good, 
moderate, or no/poor repigmentation in the three treatment groups (Group I: MEL 
+ vitamin E, Group II: MEL + 0.1% tacrolimus + vitamin E, Group III: vitamin E). 
The percentage of excellent–good repigmentation rate was higher in Group II 
than in Group I. Both clinical responses were significant compared to the control 
group (p < 0.001) 
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